Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
- Conditions
- Interventions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 136
- Registration Number
- NCT00114140
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Integrated Community Oncology Network, Jacksonville Beach, Florida, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 178
- Registration Number
- NCT00112502
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Registration Number
- NCT00109798
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 64
- Registration Number
- NCT00104988
- Locations
- 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸U.T. Cancer Institute at University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸Cottonwood Hospital Medical Center, Murray, Utah, United States
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
- Conditions
- Interventions
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00102648
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 118
- Registration Number
- NCT00100802
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 170
- Registration Number
- NCT00099125
- Locations
- 🇺🇸
Cancer Center at St. Clair Memorial Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Providence Holy Cross Cancer Center, Mission Hills, California, United States
🇺🇸Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 47
- Registration Number
- NCT00098774
- Locations
- 🇺🇸
Saint Luke's Hospital - South, Overland Park, Kansas, United States
🇺🇸Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States
🇺🇸SUNY Upstate Medical University Hospital, Syracuse, New York, United States
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00098865
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00098436
- Locations
- 🇺🇸
American Health Network - North Illinois Street, Indianapolis, Indiana, United States
🇺🇸Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.